Digitalized Differential Diagnosis Broadening in Emergency Rooms (DDX-BRO)

Effects of Digitalized Differential Diagnosis Broadening Using a Computerized Diagnostic Decision Support Tool on Diagnostic Quality in Emergency Room Patients - a Multi-centre Cluster Randomized Cross-over Trial.

10 to 35% of patients admitted to an emergency department receive an incorrect diagnosis. Not surprisingly, given the wide variety of health conditions encountered in emergency medicine, physicians often do not consider, remember, or know all possible diagnoses that fit the patient's symptoms. Nowadays, computer software (CDDS) is able to support physicians with a list of possible diagnoses by matching entered patient data to a large database with diagnoses. However, it is still unclear how the use of such a CDDS actually affects the diagnostic quality and workflow in 'real world' ER routine care. Therefore, the aim of this cluster-randomized cross-over trial is to evaluate the consequences of CDDS usage on diagnostic quality, patient outcomes and diagnostic workflow within the ER. Four ER's will provide a CDDS to the diagnosing physicians for specific periods (randomly and alternatingly allocated) in which physicians will be asked to use it for all included study patients. Outcomes between periods with and without the CDDS will be compared. Primary outcome is a diagnostic quality risk score composed of unscheduled ER revisits, unexpected hospitalization (both within 14 days), unexpected intensive medical care unit admission if hospitalized and diagnostic discrepancy between the ER discharge diagnosis and the current diagnosis after 14 days. In total, 1'184 patients will be included.

Study Overview

Status

Completed

Detailed Description

Background:

Misdiagnosis occurs in about 5% of outpatients, and in 10% to 35% of emergency room (ER) patients, sometimes with devastating medical and economic consequences. Nowadays, computerized diagnostic decision support programs (CDDS) exist, which suggest differential diagnoses (DDx) to physicians and thus have potential to improve diagnoses and hence, outcomes of patient care. The effects of such CDDS in 'real-world' ER settings are unknown. Controlled clinical trials investigating their effectiveness and safety are absent. In addition, most available CDDS are overcautious and suggest a wide variety of diagnostic options, likely increasing diagnostic resource consumption.

Objectives:

With this project, the investigators aim to understand the intended and unintended consequences of CDDS use by physicians on diagnostic quality and workflow in emergency medicine

  • on the micro-level, how CDDS affect diagnostic quality by physicians in individual emergency patients.
  • on the meso-level, how CDDS affect the diagnostic workflow in emergency departments.
  • on the macro-level, the economic and educational impact of CDDS utilization in ERs

Outcomes: Details given below

Design:

Cross sectional, multi-center, four-period cross-over controlled cluster-randomized trial. Four ER sites will randomly be allocated to one of two sequences with alternating intervention and control periods (ABAB vs. BABA) with each period lasting for two months. Recruitment will target 74 patients per period and cluster and 1'184 patients total.

Inclusion / Exclusion Criteria: Details given below

Intervention period: Details given below

Control period: Details given below.

Measurements and procedures:

For the primary outcome, data will be extracted from the electronic health records (i.e. ER diagnosis, intensive care unit admission or diagnosis after 14d if patients are still hospitalized). Additionally, patients and their general practitioner will be contacted via telephone by study nurses after 14d of study inclusion in order to collect information about patients' current diagnoses, and re-visits or hospitalization related to the initial ER visit. Data for secondary endpoints will be retrieved from the routinely collected data in the electronic health record system (e.g mortality, time to ER diagnosis, resource consumption). Additionally, interviews and focus groups with physicians will be performed to investigate diagnostic workflow changes, physician confidence and other process outcomes.

Statistical Analysis:

Statistical analysis will be based on multi-level general linear mixed modelling (GLMM) methods using appropriate post hoc techniques (e.g for subgroup analyses).

For the primary outcome (presence or no presence of a positive diagnostic quality risk score), a generalized linear mixed model (GLMM) with a binomial distribution family and exchangeable correlation structure will be performed. The GLMM takes into account a random effect for each site, resident and attending physician. Diagnosing resident and attending physicians are nested within sites. The condition (intervention and control) and the period (period 1 to 4) will be included as fixed factors under the assumption of equality of carry-over effects. Additionally, presenting chief complaint, patient's age, sex and comorbidity index will be added as covariates.

For all secondary endpoints, summary statistics appropriate to the distribution will be tabulated by treatment group. Analysis of secondary endpoints will parallel the primary analysis.

Study Type

Interventional

Enrollment (Actual)

1218

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Bern, Switzerland, 3004
        • Dept. of Internal and Emergency Medicine, Spital Tiefenau
      • Bern, Switzerland, 3010
        • Dept. of Emergency Medicine, Inselspital, University Hospital Bern
      • Solothurn, Switzerland, 3004
        • Dept. of Internal and Emergency Medicine, Buergerspital Solothurn
    • Bern
      • Münsingen, Bern, Switzerland, 3110
        • Dept. of internal and emergency medicine, Spital Münsigen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Informed Consent signed by the subject
  • Presentation to the ER with fever, abdominal pain, syncope or Non-specific complaint (NSC) as chief complaint
  • Triaged as "not vitally threatened"
  • The study subject is 18 years old or older.

Exclusion Criteria:

  • Trauma as chief complaint
  • Pregnancy
  • Worsening of a known pre-existing condition or medical referral with a definite diagnosis
  • Inability to follow the informed consent and investigation procedures
  • Previous enrolment into the current investigation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Usual Care + CDDS usage
Patients presenting to the ER and included in the study during the ER's intervention period will be treated and diagnosed by the ER physicians as usual but with support of the CDDS.
Isabel Pro - the DDx generator is a software developped for health professionals with the intention to support them in broadening their differential diagnoses. After the first patient examination, the resident is asked to enter patient symptoms into Isabel Pro, which returns a list of possible diagnoses from its underlying database that matches the entered data. The diagnosing resident physicians will be asked to consult Isabel Pro at least once within the first hour after the first patient assessement. After entering patient symptoms into the software, Isabel Pro will itself return a list with possible diagnoses derived from their underlying database. It is then free to the physician to decide whether one or more of the suggested DDx should be considered for further diagnostic or treatment procedure based on clinical judgement.
No Intervention: Usual Care
Patients presenting to the ER and included in the study during the ER's intervention period will be treated and diagnosed by the ER physicians as usual without support of the CDDS.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnostic quality risk score
Time Frame: From emergency room discharge to 14 days after emergency room discharge

Primary endpoint is a binary score indicating a diagnostic quality risk, composed of:

  • Death within 14 days after emergency room discharge (yes/no)
  • Unscheduled medical care (emergency room revisits, General Practitioner visits or hospitalization) within 14 days after emergency room discharge (yes/no)
  • Unexpected intensive care unit admission from ward within 24 hours when hospitalized (yes/no)
  • Diagnostic discrepancy between the emergency room discharge diagnosis and the current diagnosis 14 days after emergency room discharge (yes/no)
From emergency room discharge to 14 days after emergency room discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Death within 14 days after Emergency Room discharge (yes/no)
Time Frame: From emergency room discharge to 14 days after emergency room discharge
Patient died within the timeframe of emergency discharge
From emergency room discharge to 14 days after emergency room discharge
Unexpected intensive care unit admission
Time Frame: Within 24 hours from emergency room transfer to hospital ward
Number of patients with unexpected intensive care unit admission from ward within 24 hours when hospitalized (yes/no)
Within 24 hours from emergency room transfer to hospital ward
Diagnostic discrepancy
Time Frame: From emergency room discharge to 14 days after emergency room discharge
Number of patients with diagnostic discrepancy between the Emergency Room discharge diagnosis and the current diagnosis 14 days after ER discharge (yes/no)
From emergency room discharge to 14 days after emergency room discharge
Unscheduled medical care 72 hours, 7 days and 14 days
Time Frame: From emergency room discharge to 72 hours, 7 days and 14 days after emergency room discharge
Number of patients with unscheduled medical care 72 hours, 7 days and 14 days after emergency room discharge
From emergency room discharge to 72 hours, 7 days and 14 days after emergency room discharge
Length of emergency room stay
Time Frame: Time from emergency room admission to emergency room discharge, up to 24 hours
Number of hours the patient spent in emergency room routine care
Time from emergency room admission to emergency room discharge, up to 24 hours
Diagnostic tests
Time Frame: Time from emergency room admission to emergency room discharge, up to 24 hours
Number of diagnostic tests performed during emergency room routine care
Time from emergency room admission to emergency room discharge, up to 24 hours
Discharge destination
Time Frame: Timepoint of emergency room discharge (according to clinical routine, up to 24 hours)
Home / Hospital (intern) / Hospital (extern) / Nursing home / Rehabilitation / Other
Timepoint of emergency room discharge (according to clinical routine, up to 24 hours)
Number of differential diagnoses
Time Frame: Timepoint of emergency room discharge (according to clinical routine, up to 24 hours)
Number of differential diagnoses provided by the physicians at emergency room discharge
Timepoint of emergency room discharge (according to clinical routine, up to 24 hours)
CDDS potential
Time Frame: Time from emergency room admission to 14 days after emergency room discharge
Number of cases where the generated differential diagnosis list entails the diagnoses after 14 days
Time from emergency room admission to 14 days after emergency room discharge
Diagnostic error
Time Frame: From emergency room discharge to 14 days after emergency room discharge
Diagnostic error based on full chart review for a random subset
From emergency room discharge to 14 days after emergency room discharge
CDDS usage
Time Frame: Time from emergency room admission to emergency room discharge From 0 up to 24 hours.
Number of CDDS queries
Time from emergency room admission to emergency room discharge From 0 up to 24 hours.
Physician confidence calibration, advice seeking and collaboration
Time Frame: Exact timepoints to be defined, up to a maximum of 9 months. From June 2022 to March 2023
Assessed by qualitative methods such as observations of physicians or interviews and focus groups with physicians (no patients directly involved).
Exact timepoints to be defined, up to a maximum of 9 months. From June 2022 to March 2023
Length of hospital stay
Time Frame: Time from hospital admission to hospital discharge, up to 18 days
Number of days the patient was hospitalized (if hospitalized)
Time from hospital admission to hospital discharge, up to 18 days
Resource consumption in the Emergency Department
Time Frame: Time from emergency room admission to emergency room discharge, up to 24 hours
Resource consumption (total costs for personnel and diagnostics) during emergency room
Time from emergency room admission to emergency room discharge, up to 24 hours
Resource consumption
Time Frame: Time from emergency room admission to emergency room discharge, up to 18 days
Resource consumption (total costs for personnel and diagnostics) during hospitalization
Time from emergency room admission to emergency room discharge, up to 18 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Wolf Hautz, Prof. MD, Prof. MD

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 9, 2022

Primary Completion (Actual)

July 13, 2023

Study Completion (Actual)

July 13, 2023

Study Registration Dates

First Submitted

March 21, 2022

First Submitted That Met QC Criteria

April 25, 2022

First Posted (Actual)

April 26, 2022

Study Record Updates

Last Update Posted (Actual)

July 21, 2023

Last Update Submitted That Met QC Criteria

July 20, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Researchers who wish to use IPD for a nested study need to submit a proposal to the Sponsor-Investigator and request permission. A concept sheet describing the planned analyses must be approved by the sponsor-investigator and PIs of the participating sites. Nested studies might need separate ethics permission.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Emergencies

Clinical Trials on Isabel Pro - The DDx generator (CDDS)

3
Subscribe